The estimated Net Worth of Joseph Baroldi is at least $958 Tisíc dollars as of 15 April 2024. Joseph Baroldi owns over 10,838 units of Avidity Biosciences stock worth over $958,244 and over the last 4 years Joseph sold RNA stock worth over $0.
Sign up
Joseph Baroldi RNA stock SEC Form 4 insiders trading
Joseph has made over 4 trades of the Avidity Biosciences stock since 2023, according to the Form 4 filled with the SEC. Most recently Joseph exercised 10,838 units of RNA stock worth $439,373 on 15 April 2024.
The largest trade Joseph's ever made was exercising 10,838 units of Avidity Biosciences stock on 15 April 2024 worth over $439,373. On average, Joseph trades about 2,302 units every 38 days since 2021. As of 15 April 2024 Joseph still owns at least 23,637 units of Avidity Biosciences stock.
You can see the complete history of Joseph Baroldi stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Joseph Baroldi's mailing address?
Joseph's mailing address filed with the SEC is 2855 GAZELLE COURT, , CARLSBAD, CA, 92010.
Insiders trading at Avidity Biosciences
Over the last 4 years, insiders at Avidity Biosciences have traded over $8,545,325 worth of Avidity Biosciences stock and bought 2,050,000 units worth $36,900,000 . The most active insiders traders include Investments, Lpwong Roderic..., Lilly & Co Eli a Asset Management, Lp Chen B.... On average, Avidity Biosciences executives and independent directors trade stock every 34 days with the average trade being worth of $3,142,336. The most recent stock trade was executed by Arthur A Levin on 19 August 2024, trading 5,000 units of RNA stock currently worth $6,200.
What does Avidity Biosciences do?
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
What does Avidity Biosciences's logo look like?
Complete history of Joseph Baroldi stock trades at Ionis Pharmaceuticals Inc a Avidity Biosciences
Avidity Biosciences executives and stock owners
Avidity Biosciences executives and other stock owners filed with the SEC include:
-
Sarah Boyce,
Pres, CEO & Director -
Michael F. MacLean,
Chief Financial Officer -
Dr. Troy Edward Wilson J.D., Ph.D.,
Co-Founder & Chairman -
Teresa McCarthy,
Chief HR Officer -
Dr. John W. Wallen III,
VP of Intellectual Property, Gen. Counsel & Sec. -
Kathleen Gallagher,
Sr. VP of Corp. Communications & Investor Relations -
Dr. Arthur A. Levin Ph.D.,
Chief Scientific Officer -
Dr. W. Michael Flanagan Ph.D.,
Chief Technical Officer -
Dr. Frank McCormick Ph.D.,
Scientific Founder & Member of Scientific Advisory Board -
Prof. Mark E. Davis,
Scientific Founder, Member of Scientific Advisory Board and Member of Board of Mang.s -
Arthur A Levin,
Director -
John B Moriarty,
Chief Legal Officer -
Michael F Mac Lean,
Chief Financial Officer -
Jae B. Kim,
Chief Medical Officer -
Troy Edward Wilson,
Director -
Asset Management, Lp Chen B...,
-
Lilly & Co Eli,
-
Tamar Thompson,
Director -
Jean Jinsun Kim,
Director -
Joseph Baroldi,
Chief Operating Officer -
Sarah Boyce,
President and CEO -
Noreen Henig,
Director -
Edward M. Md Kaye,
Director -
Carsten Boess,
Director -
Roderick Wong,
Director -
Investments, Lpwong Roderic...,
MP and CIO -
Eric Mosbrooker,
Director -
Teresa Mc Carthy,
Chief Human Resources Officer -
W. Michael Flanagan,
CSTO -
Simona Skerjanec,